Search
News
VNET Q2 2026 Earnings: Wholesale Growth Lifts EBITDA Despite Margin Pressure
VNET Group’s Q2 2026 revenue rose 14.2% to RMB2.78 billion as wholesale IDC revenue increased 29.3% to RMB1.10 billion. Adjusted EBITDA grew 25.4% to RMB918.3 million and margin expanded to 33.0%, helped by lower operating expenses. However, GAAP gross margin fell to 18.2% as capacity-related depreciation increased, operating cash flow declined to RMB218.1 million, and the attributable net loss widened to RMB135.6 million. VNET reaffirmed its full-year revenue, adjusted EBITDA and RMB10 billion-RMB12 billion capital-expenditure guidance.
TradingKey
Tue, Aug 18
Baidu Q2 2026 earnings: AI cloud growth could not offset marketing pressure
Baidu’s Q2 2026 revenue fell 4% year over year to RMB31.3 billion, while diluted earnings per ADS dropped to RMB5.74 from RMB20.35. AI Cloud Infra revenue rose 50% to RMB7.3 billion and helped core AI-powered business grow 25%, but online marketing revenue declined 19%. Operating cash flow improved to RMB3.4 billion from an outflow a year earlier, although RMB11.4 billion of capital spending pushed free cash flow to negative RMB8.0 billion. Lower investment-related gains and a larger foreign-exchange loss also weighed on net income.TradingKey
Tue, Aug 18
Flexsteel Fiscal Q4 2026 Earnings: Tariff Refunds Lift GAAP Profit
Flexsteel’s fiscal Q4 2026 net sales rose 0.7% to $115.4 million, while GAAP diluted EPS increased to $2.58 from $1.89. A $9.0 million tariff refund lifted gross margin to 30.0% and GAAP operating margin to 14.2%, but adjusted operating margin fell to 7.1% from 9.0% and adjusted EPS declined to $1.33. Quarterly operating cash flow was $24.3 million, compared with $62.6 million of share repurchases. For fiscal Q1 2027, Flexsteel guided to $111 million-$115 million in sales and a 6.5%-7.0% GAAP operating margin.
TradingKey
Mon, Aug 17
Pioneer Power Q2 2026 Earnings: Revenue Falls as Gross Margin Improves
Pioneer Power Solutions’ Q2 2026 revenue fell 40.0% year over year to $5.0 million as sales and rentals of e-Boost mobile EV charging solutions declined. Diluted net loss widened to $0.19 per share from $0.12, while gross margin improved to 19.6% from 15.7% on better operating efficiency. Backlog rose 32% sequentially to $18.4 million, and management projected approximately $15 million of revenue for the second half of 2026, more than 60% above first-half revenue.
TradingKey
Mon, Aug 17
Newton Golf Q2 2026 earnings: Manufacturing transition drives a 36% sales decline
Newton Golf’s Q2 2026 revenue fell 36% year over year to $1.316 million as a manufacturing transition and temporary carbon fiber constraints reduced output and delayed shipments. Gross profit was $911,000, while gross margin rose to 69.2% from 67.6% on a more favorable product and channel mix. Net loss widened to $2.278 million, or $0.49 per share, from $1.520 million, or $0.34 per share. Post-quarter financing improved financial flexibility, but the company said it expects to require additional capital.
TradingKey
Fri, Aug 14
Greenland Q2 2026 Earnings: Product Mix and Lower G&A Restore Profitability
Greenland Technologies’ Q2 2026 revenue increased 37.6% to $29.88 million, while diluted EPS improved to $0.13 from a $0.20 loss. Gross margin expanded to 31.9% from 26.5% as transmission volume rose and the product mix shifted toward higher-value products. Operating income reached $5.98 million, helped by lower stock-based compensation and reduced G&A expense. However, first-half operating cash flow was only $0.09 million despite $10.69 million in net income, making working-capital conversion an important issue to monitor.
TradingKey
Fri, Aug 14
Suncrete Q2 2026 Earnings: Revenue Rises 146% While GAAP Loss Widens
Suncrete (NASDAQ: RMIX) reported Q2 2026 revenue of $97.2 million, up 146% year over year, while diluted loss per share widened to $0.72 from $0.24. Adjusted EBITDA rose to $13.5 million from $7.0 million, although its margin fell to 13.9%. GAAP results included $12.2 million of acquisition-related costs and a $26.9 million non-cash business-combination charge. Ready-mix volume increased 123%, and management maintained fiscal 2026 revenue guidance of $420 million to $480 million following recently completed acquisitions.
TradingKey
Fri, Aug 14
Acurx Q2 2026 earnings: per-share loss narrows as share count rises
Acurx Pharmaceuticals’ Q2 2026 results showed a net loss of $2.25 million, nearly unchanged from a year earlier, while basic and diluted loss per share narrowed to $0.53 from $1.89. R&D expense rose 104% to $1.07 million as manufacturing and consulting costs increased for the recurrent CDI trial program, offset by a 29% decline in G&A expense. Quarter-end cash reached $10.66 million after equity financing, while the larger share count explains most of the per-share improvement and highlights dilution as a key investor consideration.
TradingKey
Fri, Aug 14
RLX Technology Q2 2026 Earnings: Gross Margin Expands as Revenue Rises 14.8%
RLX Technology’s Q2 2026 revenue increased 14.8% to RMB1.01 billion, while gross margin expanded to 35.4% from 27.5% as international growth, revenue mix, and supply-chain optimization supported profitability. GAAP income from operations rose 234.7% to RMB130.4 million, but GAAP net income increased only 1.6% to RMB222.0 million as non-operating income declined. Operating cash flow turned to an RMB63.2 million outflow, and international business accounted for 68.5% of quarterly revenue.
TradingKey
Fri, Aug 14
Nu Q2 2026 Earnings: Net Income Reaches a Record $1.1 Billion
Nu Holdings’ Q2 2026 gross revenue reached nearly $5.9 billion, rising 39% year over year on an FX-neutral basis, while net income hit a record $1.1 billion, up 49%. Net interest income was $3.7 billion, and risk-adjusted net interest margin widened to 12.4% from 9.5% in Q1 as the credit portfolio expanded and seasonal early delinquencies improved. Customers reached 139 million, but the 90-plus-day nonperforming loan ratio rose to 6.9% and the efficiency ratio increased sequentially amid marketing, real estate, and international expansion spending.
TradingKey
Thu, Aug 13
Health In Tech Q2 2026 Earnings: Lower Revenue and Higher Costs Drive a Loss
Health In Tech (Nasdaq: HIT) reported Q2 2026 revenue of $8.1 million, down 13.5% year over year, and diluted EPS of $(0.04), versus $0.01 a year earlier. Gross margin fell to 48.7% from 67.7% as cost of revenue rose, while adjusted EBITDA swung to a $1.3 million loss. Operating cash flow was negative $2.9 million. The company nevertheless reaffirmed 2026 revenue guidance of $45 million to $50 million, supported by contracted revenue and a $66.3 million pipeline whose conversion and recognition timing remain central execution questions.
TradingKey
Thu, Aug 13
Sensus Healthcare Q2 2026 earnings: Lower unit sales drive a 68.5% revenue decline
Sensus Healthcare (NASDAQ: SRTS) reported Q2 2026 revenue of $2.3 million, down 68.5% year over year, as reported unit volume fell to 11 from 19 and financing approval timing shifted revenue from eight units into Q3. Gross margin declined to 34.8% from 39.7%, while diluted loss per share widened to $0.53 from $0.06. A $5.7 million deferred-tax valuation allowance lifted the GAAP net loss to $8.7 million. Quarter-end cash, restricted cash and cash equivalents were $15.2 million, with no revolving-credit borrowings.
TradingKey
Thu, Aug 13
York Space Systems Q2 2026 Earnings: Gross Margin Improves as Revenue Guidance Falls
York Space Systems’ Q2 2026 revenue rose 10% to $92.5 million, while gross profit climbed 133% to $22.2 million and gross margin expanded 13 percentage points to 24%. However, net loss widened to $39.3 million, or $0.31 per diluted share, as operating expenses more than doubled. Backlog ended June at $592 million, down 8% from March but up 9% from year-end. The company lowered full-year 2026 revenue guidance to $375 million-$405 million, citing a shift in U.S. government procurement toward slower-starting IDIQ awards.
TradingKey
Thu, Aug 13
KinderCare Q2 Fiscal 2026 Earnings: Lower Enrollment Pressures Profitability
KinderCare’s Q2 fiscal 2026 revenue slipped 0.4% to $697.5 million as 4.0% lower early-childhood enrollment outweighed higher tuition and school-age growth. GAAP diluted EPS fell to a $0.07 loss from $0.33 earnings, while adjusted EBITDA declined 23.6% to $63.0 million. Operating income narrowed to $2.4 million as the prior-year comparison included Employee Retention Credits and the company recorded higher service costs and impairment charges. KinderCare also closed 49 early-childhood centers and updated full-year revenue guidance to $2.66 billion-$2.70 billion.
TradingKey
Thu, Aug 13
Cineverse Q1 FY2027 Earnings: Acquisitions Lift Revenue 175%
Cineverse’s Q1 FY2027 revenue rose 175% to $30.6 million as acquired Advertising Technology and Media Services contributed $19.4 million in their first full quarter. Adjusted EBITDA improved by $2.6 million to $0.5 million, but the GAAP net loss attributable to common stockholders widened to $5.8 million and direct operating margin fell to 35% from 57%. Operating cash flow improved by more than $13 million year over year. Cineverse reaffirmed FY2027 guidance of $115 million to $120 million in revenue and $10 million to $20 million in adjusted EBITDA.
TradingKey
Thu, Aug 13
cbdMD Q3 FY2026 Earnings: Revenue Grows 20% as Gross Margin Narrows
cbdMD reported fiscal third-quarter 2026 net sales of $5.6 million, up 20% year over year, while diluted loss per share narrowed to $0.11 from $0.21. Gross margin fell to 54.7% from 61.5% as wholesale mix, repacking expenses, and regulatory-related inventory reserves raised costs. The GAAP operating loss widened to $1.13 million, although adjusted EBITDA loss improved to $508,000. Wholesale sales increased 61%, Bluebird Botanicals contributed more than $0.5 million, and the company began cost actions targeting $100,000 to $150,000 in monthly savings.
TradingKey
Thu, Aug 13
Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion
Nektar Therapeutics’ Q2 2026 revenue fell to $10.1 million from $11.2 million, while net loss narrowed slightly to $40.6 million and loss per share improved to $1.23 from $2.95 as the weighted share count more than doubled. R&D expense rose about 31% to $39.1 million as the company prepared the Phase 3 ZENITH AD program and related manufacturing. Cash and marketable securities reached $1.02 billion, and management said the runway extends into Q3 2028, beyond initial Phase 3 readouts expected in mid-2028.
TradingKey
Thu, Aug 13
Aethlon Medical Fiscal Q1 2027 results: Lower expenses narrow the net loss
Aethlon Medical’s fiscal Q1 2027 results showed operating expenses falling 11.9% to $1.58 million, helping narrow the net loss to $1.55 million from $1.76 million. Basic and diluted loss per share improved to $4.02, though the weighted-average share count increased more than ninefold. Cash stood at $4.93 million on June 30, 2026, and a post-quarter public offering raised about $4.0 million in gross proceeds. Clinically, Aethlon dosed the first participant in the final cohort of its Australian Phase 1 Hemopurifier oncology study, while emphasizing that early biomarker observations remain preliminary.
TradingKey
Thu, Aug 13
Soluna Q2 2026 earnings: Revenue rises 145% as net loss widens
Soluna Holdings’ Q2 2026 revenue rose 145% year over year to $15.1 million, though growth was 73% excluding a new gross presentation for pass-through electricity costs. Net loss widened to $22.6 million from $7.8 million, while adjusted EBITDA loss improved sequentially to $1.6 million. Data hosting drove the top line, but Briscoe maintenance, Kati 1 ramp costs and added depreciation reduced gross profit to $766,000. Soluna ended June with $113.4 million of unrestricted cash as its development pipeline expanded to approximately 6.3 GW.
TradingKey
Thu, Aug 13
HeartBeam Q2 2026 results: Cash-burn outlook improves as net loss holds near $5 million
HeartBeam’s Q2 2026 results showed a $5.0 million net loss, or $0.10 per share, while operating cash use declined to $3.3 million. Total operating expenses stayed near $5.1 million as lower R&D spending offset higher SG&A costs, including former-CEO-related stock compensation and severance. Cash and equivalents reached $8.7 million after equity financing, and HeartBeam lowered its 2026 net operating cash outflow outlook to below $14.0 million. Commercial agreements, clinical studies and expansion beyond arrhythmia assessment remain central to its next phase.
TradingKey
Thu, Aug 13
Featured Tools
Top News
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
Bloom Energy Q3 Revenue Up 138% YoY, EPS Swings to Profit, But Shares Tumble 7% After Hours
Today’s Market Recap: Nasdaq Drops 2.60%, Meta Slumps 7%, Oil Surges Past $113, Gold Plunges Toward $4,000
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
